Mitochondrial dynamics in the neonatal brain – a potential target following injury?

Adam Jones¹ and Claire Thornton²

¹Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King’s College London, London SE1 7EH, U.K.; ²Department of Comparative Biomedical Sciences, Royal Veterinary College, London NW1 0TU, U.K.

Correspondence: Claire Thornton (cthornton@rvc.ac.uk)

The impact of birth asphyxia and its sequelae, hypoxic–ischaemic (HI) brain injury, is long-lasting and significant, both for the infant and for their family. Treatment options are limited to therapeutic hypothermia, which is not universally successful and is unavailable in low resource settings. The energy deficits that accompany neuronal death following interruption of blood flow to the brain implicate mitochondrial dysfunction. Such HI insults trigger mitochondrial outer membrane permeabilisation leading to release of pro-apoptotic proteins into the cytosol and cell death. More recently, key players in mitochondrial fission and fusion have been identified as targets following HI brain injury. This review aims to provide an introduction to the molecular players and pathways driving mitochondrial dynamics, the regulation of these pathways and how they are altered following HI insult. Finally, we review progress on repurposing or repositioning drugs already approved for other indications, which may target mitochondrial dynamics and provide promising avenues for intervention following brain injury. Such repurposing may provide a mechanism to fast-track, low-cost treatment options to the clinic.

Introduction

The cellular energy required by the developing brain around the time of birth and during early life is substantial, emphatically illustrated by the rapid increase from 27 to 80% of its adult weight within the first 2 years of life [1]. It is unsurprising, therefore that efficiently functioning mitochondria coupled with a ready supply of oxygen are pivotal to meet the ATP demands of a rapidly expanding brain. However, mitochondria not only live up to their ‘powerhouse’ reputation, they are also hubs for immune response, calcium buffering as well as regulating reactive oxygen species (ROS) production and triggering programmed cell death [2–4]. This expanded repertoire of functions ascribed to mitochondria has emerged in part due to significant advances in our understanding of its molecular regulation. It is now clear that in addition to the roles mentioned above, mitochondria can adapt morphologically, dictated by the presence or absence of environmental stress, and that such dynamic adaptations are tailored to specific mitochondrial functions [5,6]. Mitochondrial dynamics, the process of balanced cycling through fission and fusion, are essential for maintaining cellular health and dysfunctional dynamics have been implicated in almost all pathological conditions with any element of bioenergetics compromise [6]. Focussing on the brain, perturbations in mitochondrial dynamics have been identified in numerous neurodegenerative conditions (e.g. Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis) as well as stroke, traumatic brain injury and neurodevelopmental conditions such as Autism Spectrum Disorder [7–11]. In this review, we introduce the molecular players involved in regulating mitochondrial dynamics, and then describe the effect of hypoxic–ischaemic (HI) injury, particularly after birth asphyxia, on these processes. Finally, we evaluate the potential of repurposing drugs in order to provide therapies to restore balanced mitochondrial fission and fusion, which may be considered for therapeutic intervention in neonatal hypoxic–ischaemic encephalopathy (HIE).
Mitochondrial health is managed by interconnected mechanisms

Mitochondrial function is governed by a series of regulated mechanisms that, in addition to fusion and fission (division [5]), include mitochondrial biogenesis [12] and mitophagy (Figure 1; [13]) as well as elegant machinery designed to transport the mitochondria around the microtubule network [14]. Mitochondrial fusion provides a means to share mitochondrial contents including mitochondrial DNA (mtDNA), proteins and lipids. As such, minor defects such as low-level mtDNA mutation or accumulating ROS can be ‘diluted out’ by fusion of the impaired mitochondrion into more complex mitochondrial network [15]. Mitochondrial fusion can also promote increased oxygen consumption, oxidative phosphorylation and therefore higher yields of ATP [16]. Mitochondrial fission is essential for quality control, as fragmentation of a large mitochondrion into smaller parts can isolate areas of damage for subsequent clearance. Biogenesis provides new mitochondria for the cellular pool, whereas mitophagy is the process of recycling dysfunctional mitochondria, for example with damaged mtDNA or with loss of mitochondrial membrane potential (Δψm; [17]).

The molecular mediators of mitochondrial dynamics

As mitochondria are double membrane-bound organelles, mitochondrial fusion requires two separate events, one to fuse the inner mitochondrial membrane (IMM) and one for the outer mitochondrial membrane (OMM). Both are governed by large dynamin-related GTPases; mitofusin (MFN) 1 and MFN 2 are responsible for OMM fusion, with Optic Atrophy (OPA1) mediating IMM fusion [18]. Fission is driven by the GTPase Dynamin-related (Drp1), normally cytosolic, which is recruited to the mitochondrion through binding to one of Mitochondrial Fission Factor (MFF), Mitochondrial Division (MiD) 49, MiD51 or Fission (Fis)1, located at the OMM [5].

Mitochondrial fusion

OPA1 exists in long (L-OPA1) and short (S-OPA1) forms, both of which are required for OPA1 function [19–22]. OPA1 is imported into the mitochondria via an N-terminal mitochondrial targeting sequence, followed by mitochondrial processing peptidase (MPP) cleavage to generate L-OPA1 [23]. L-OPA1 localises to the mitochondrial intermembrane space, bound to the IMM by an N-terminal transmembrane (TM) domain [22–24]. L-OPA1 is then proteolytically cleaved to S-OPA by OMA1 and YME1L peptidases localised to the IMM; once cleaved, S-OPA is soluble. Co-operation between L-OPA1 and cardiolipin (a negatively charged lipid abundant in the IMM) is sufficient for IMM fusion although S-OPA1 can facilitate this process further [25]. IMM fusion is therefore dependent on OMA1 and YME1L activities to ensure the correct ratio of L-OPA and S-OPA; excessive cleavage of L-OPA1 will
allow unopposed mitochondrial fission. OPA1 null MEFs results in a fragmented mitochondrial network due to fusion incompetence [21]. Complete ablation of OPA1 is embryonic lethal in mice, whereas overexpression is also toxic; however, mild overexpression is compatible with life and has shown OPA1 to be protective in response to cell death stimuli, along with restoration of ATP production and the morphology of mitochondrial networks [20,26–28].

MFN1 and MFN2 share 77% amino acid sequence similarity and are required for OMM fusion as they are capable of tethering neighbouring mitochondria, allowing GTP-dependent fusion to take place [29]. The activity of MFNs is regulated by post-translational modification, including ubiquitination and phosphorylation [30,31]. Phosphorylation of MFNs by PTEN-induced serine/threonine kinase (PINK)1 can promote subsequent ubiquitination by Parkin, leading to mitophagy and degradation [32,33]; degradation is also observed following ubiquitination by MARCH5 leading to mitochondrial fission [34]. ERK1/2 phosphorylates MFN1 leading to increased mitochondrial fission [35] although in vivo confirmation of this regulation remains [36]. MFN1 and MFN2 have tissue-specific expression and differences in GTPase activities [37,38]. The brain showed lower mRNA expression for both MFNs compared with heart, liver or skeletal muscle with MFN1 more highly expressed than MFN2 [38]. Purified recombinant MFN1 GTPase activity was approximately eight-fold higher than MFN2, whereas MFN2 has a higher affinity for binding GTP [37]. These differences may reflect evidence suggesting that MFN1 drives the initial tethering of the mitochondrial membranes together, whereas MFN2 may act in the tethering of the ER to the mitochondria [39]. Indeed although there is redundancy, genetic studies suggest individual roles for MFN1 and MFN2 during development [40]. However, assignment of such specific functions between MFNs is still being debated [41].

Mitochondrial fission

The initiation of mitochondrial fission is reliant on organelle interaction and protein phosphorylation. Mitochondrial fission is dictated by the endoplasmic reticulum, which can wrap around the mitochondrion at the chosen site and initiate constriction [42]. DRP1 then translocates from the cytosol, binds to OMM protein partners to spiral around the mitochondrion, constricting and finally severing both mitochondrial membranes, powered by GTP hydrolysis [15,19,43–45]. DRP1 is regulated by multiple post-translational modifications, including phosphorylation at S616 by ERK, and S637 by Protein Kinase A (PKA) or AMP-activated protein kinase (AMPK) [46,47]). Phosphorylation of DRP1 at S616 promotes its translocation to the mitochondria, and observations of DRP1-pS616 correlate with mitochondrial fragmentation [48–50]. DRP1 phosphorylation at S637 inhibits fission in part through attenuating DRP1 GTPase activity [51]. This inhibition is reversible as dephosphorylation by the calcium-dependent phosphatase calcineurin [52] and subsequent rephosphorylation at S616 results in fission [46,48–50,53]. Further regulation is provided by A-kinase anchoring protein (AKAP)1, which anchors PKA at the OMM in order to phosphorylate DRP1 at S637 [54]. Phosphoregulation of DRP1 at S637 promotes cell survival and has been identified as key factor in determining ischaemic sensitivity post-injury [46,48].

Unlike other members of the dynamin family, DRP1 does not possess a pleckstrin homology domain, which would normally facilitate phospholipid binding and membrane localisation. Therefore DRP1 recruitment to the mitochondrion relies on interaction with a number of binding partners already anchored to the OMM, including mitochondrial fission 1 protein (FIS1), MFF and mitochondrial dynamics protein (MiD)49/MIEF2 and MiD51/MIEF1 [46,55–57]. MFF is considered the major DRP1-binding partner, capable of promoting DRP1 GTPase activity, and loss of MFF results in significant mitochondrial fusion [58]. MFF is itself regulated by phosphorylation by AMPK that increases mitochondrial fission [59], and this may trigger an alternative pathway to mitophagy in response to cellular stress [60]. The role of FIS1 in DRP1-mediated mitochondrial fission is still being clarified as knockdown of FIS1 promotes fused mitochondrial morphology, but the interaction between DRP1 and FIS1 is weak [61]. A combined MFF/FIS1 knockout model determined an additive mitochondrial hyperfusion effect suggesting that FIS1 acts independently of MFF to promote fission [62]. One possible mechanism may be by inhibition of fusion rather than promoting fission; a recent study identified that FIS1 interacts strongly with pro-fusion OPA1 and MFNs, inhibiting their GTPase activity [61]. Alongside MFF, MiD49/51 bind and recruit DRP1 to the OMM, mediating DRP1 oligomerisation and its encircling of the mitochondrion. However, in contrast with MFF, MiD49/51 binding inhibits DRP1 GTPase activity [63]. Further uncertainty is added when considering that both MiD49/51 knockdown and overexpression studies yield a fusion phenotype [62]; a possible explanation may lie in the influence of cellular environment and the phosphorylation state of DRP1.

The fate of mitochondria following fission is based on mitochondrial Δψ. Healthy mitochondria are fed back into the cycle to be used as substrates for biogenesis, whereas those with perturbed Δψ trigger the accumulation and dimerisation of PINK1 around the OMM [15,64]. On autophosphorylation, PINK1 recruits the E3 ubiquitin ligase Parkin, and ubiquitin, marking the mitochondrion for LC3B recruitment into an autophagosome and subsequent

© 2022 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
autolysosomal degradation, in a process termed mitophagy [65,66]. Of relevance to the HI brain was the identification of a PINK1/Parkin-independent pathway to mitophagy, regulated by hypoxia. Src-phosphorylated FUNDC1 is located at the OMM and becomes dephosphorylated during hypoxia which permits binding to LC3B and autolysosomal degradation [67]. Biogenesis from fissioned mitochondria ‘seeds’ relies on the replication of mtDNA, and subsequent transcription and translation of genes critical for mitochondrial function such as electron transport proteins [12]. Key regulators of this process are the transcription factors Tfam, NRF1/2 and PGC1α, this last being described as a master regulator of biogenesis [68]. A recent study has further identified mechanisms governing the fissioned mitochondrial fate, dependent on the position of the fission site [69]. Fission events taking place at a midpoint region of the mitochondrion were identified as DRP1–MFF-dependent and led to biogenesis, whereas those taking place at the periphery were governed by DRP1–FIS1 interactions. These FIS1-mediated fission events created smaller mitochondria which were subsequently targeted for mitophagy, minimising the mass of material to be recycled [69]. Peripheral fission events were found to follow a decrease in Δψm and an increase in ROS and calcium signalling, promoting cell survival after stress stimuli [69]. However, mitochondrial biogenesis and mitophagic quality control are not the focus of this paper, and the reader is directed to excellent, comprehensive reviews [70–72].

Energy metabolism fails in neonates after birth asphyxia

Birth asphyxia leading to HIE affects 1–2 in every 1000 infants in the United Kingdom and far more in low resource countries [73,74]. The consequences for babies severely affected are significant including long-lasting neurological impairments (cerebral palsy, epilepsy) and death. Clinical MRI studies report that HIE is characterised predominantly by evolving lesions in grey matter structures (thalamus, basal ganglia), cortical abnormalities and, to a lesser extent, associated white matter injury. Neurons are most vulnerable, with the extent of lesion size being strongly associated with the severity of long-term impairments [74].

Brain injury following asphyxia occurs as a result of impaired neuronal energy metabolism and evolves with time, passing through distinct phases (Figure 2). The primary energy failure phase (30–60 min) encompasses the initial asphyxia insult depriving the tissue of oxygen and glucose, leading to immediate depletion of ATP, anaerobic respiration, excessive glutamate release and necrotic death [75,76]. Reperfusion results in latent phase 6–12 h after initial insult, characterised by a partial recovery from oxidative stress. However, a secondary energy failure phase occurs in which mitochondrial dysfunction, oxidative stress, neuroinflammation and programmed cell death are features, and which lasts up to 72 h [75,77–79]. Finally a tertiary (months) phase occurs in which chronic neuroinflammation persists and neurogenesis and myelination are impaired [80].

The latent phase is considered a therapeutic window for intervention as high-energy phosphate levels are recovered to baseline levels due to partial restoration of tissue oxygenation [75,81]. However, currently the only clinically available treatment is therapeutic hypothermia (cooling to 33–34°C for 72 h, following by a slow rewarming at 0.5°C per hour), initiated within 6 h of birth [82–86]. Therapeutic hypothermia acts to restore metabolic and cellular energy state homeostasis and provides proof-of-principle that a therapy administered following the initial injury can be effective in preventing the long-lasting effects of HI. However, it has a limited success rate, highlighting the need for additional synergistic or stand alone therapy [84,86,87].

Mitochondria permeabilise following neonatal HI injury

HI injury triggers an array of pathophysiological outcomes (Figure 2). Following the initial HI injury, a cascade of signalling events is initiated including calcium overload, inflammation, generation of ROS and excitotoxicity and culminating in activation of a variety of programmed cell death pathways [88–94]. Mitochondrial dysfunction is a key characteristic linking these diverse observations [95,96] and in animal models of neonatal HI, oxidative phosphorylation and calcium homeostasis are impaired [97–99]. Indeed electron microscopy identified ultrastructural changes in mitochondrial cristae due to calcium influx following HI in neonatal rats [90]. In addition, in response to HI, the OMM becomes leaky due to the formation of activated Bax/Bak pores allowing passage of cytochrome c and apoptosis-inducing factor (AIF) from the mitochondrial intermembrane space (IMS) into the cytosol. Once released, AIF and cytochrome c initiate a cascade resulting in activation of caspases, degradation of DNA and ultimately apoptotic cell death [100,101]. As such, genetic and pharmacological inhibition of Bax is protective from HI in the immature brain [102,103].
Figure 2. Secondary energy failure following birth asphyxia results in mitochondrial impairment

The primary phase of injury lasts over the time of the asphyxia and results in initial ATP depletion and necrosis. A latent phase lasting from 1 to 12 h following injury occurs in which ATP levels recover to baseline and where therapeutic interventions are initiated. A secondary injury phase is characterised by multiple cellular processes impairing mitochondrial function leading to BAX-mediated mitochondrial outer membrane permeabilisation (MOMP), mitochondrial fission and culminates in cell death.

Mitochondrial dynamics are targeted in the brain following ischaemia–reperfusion injury

Imbalance of mitochondrial fission and fusion has been observed in a number of adult ischaemia–reperfusion (I/R) injuries including kidney [104] and heart [105], where mitochondrial fission is a driver of injury. Genetic or pharmacological inhibition of DRP1 or promotion of mitochondrial fusion results in increased cell survival and restoration of tissue function [106–108].

Similar observations have been made in brain in models of cerebral ischaemia where increased mitochondrial fission (or decreased fusion) is associated with cell death and development of injury [109]. In vitro, increased fission is observed following oxygen-glucose deprivation in hippocampal [110,111] and microglial [112] cell lines, neurons [79,113], astrocytes [114] and microglia [115]. Increased mitochondrial fission and/or pro-fission DRP1 phosphorylation is apparent in rodent models of middle cerebral artery occlusion (MCAO) and DRP1 inhibition results in preservation of tissue [110,116,117]. Mitochondrial fission is also promoted through influx of calcium, activating
In the neonatal brain, alterations in mitochondrial dynamics have been demonstrated in vivo using the Vannucci model of neonatal HI. Increased gene expression of MFN1 and FIS1 [120] and decreased expression of OPA1 [79] has been observed at 24 h post-injury; no changes have been observed at earlier time points [79,120]. Post-translational modification of OPA1 occurs soon after HI resulting in increased cleavage of L-OPA1 to S-OPA1 and remaining through 24 and 48 h post-injury [79,120]. Decreases in phosphorylated DRP1 (S637) are also reported at 24 h post-injury indicative of a shift towards fission, although FIS1 protein expression over this period remains unchanged despite the increases in gene expression [120]. Decreased mitochondrial size was observed in brain sections stained for the mitochondrial marker TOMM20 at 24 h following neonatal HI [121]. The authors also found that hypoxia alone triggers decreased mitochondrial size but HI induced a more profound change, which was sex-specific; fission can resist this ischaemia-mediated bias towards fission [28,118] presumably overcoming mechanisms promoting pro-fission DRP1 phosphorylation.

Pharmacological regulators of mitochondrial dynamics – potential therapies?

There is an urgent need to identify new treatments for neonatal brain injury following birth asphyxia and a number of potential therapies are showing promise [122]. However, given the impact of impaired fission and fusion on multiple aspects of the injury, deriving therapeutic compounds targeting mitochondrial dynamics may address the current paucity of treatments. Although the majority of these are compounds still in preclinical development (e.g. echinacoside [123], Drpitor [124]), there are an increasing number of studies centred around repurposing (or repositioning) drugs already in use clinically, with advantages including lower cost, reduced development time and pre-existing safety profiles [125]. There are a number of repurposed therapies reported to alter mitochondrial respiration (e.g. Methylene Blue [126]), however, here we will focus on those currently emerging treatments (in clinical use for other indications) that exert at least part of their effects through modulation of mitochondrial dynamics.

Leflunomide

Leflunomide is approved for rheumatoid arthritis treatment as an anti-inflammatory, and is being considered for repurposing as a pancreatic cancer therapy [127]. A recent high-throughput screen identified Leflunomide as a small molecule activator of mitochondrial fusion through a pathway dependent on MFN1/2. Biochemically, Leflunomide inhibits dihydroorotate dehydrogenase (DHODH), an IMM enzyme that catalyses de novo synthesis of pyrimidines. Depletion of pyrimidines results in increased expression of MFN1/2 and mitochondrial fusion and pretreatment with Leflunomide prevented doxorubicin-mediated apoptosis in MEFs [128,129]. Leflunomide was also found to oppose mitochondrial fission in triple-negative breast cancer cells [130]. Leflunomide pretreatment (10–40 mg/kg) has preserved mitochondrial ΔΨm, reduced apoptosis and provided antioxidant effects in adult rodent I/R models in the kidney [131,132], intestine [133] and liver [134]. However, Leflunomide has not been tested in neonatal disease models post-injury and the dosage used in the I/R studies was significantly higher than in use for rheumatoid arthritis (adults: 100 mg per day initially, then 10–20 mg per day).

Pioglitazone

Pioglitazone (PGZ) is a member of the thiazolidinedione family used to reduce insulin resistance and regulate blood glucose, hence in clinical use for type 2 diabetes [135]. PGZ acts as a PPAR agonist, known to increased PGC1α activity and mitochondrial biogenesis [136]. However, more recently, PGZ was shown to protect the expression of fusion (OPA1, MFN1/2) and fission (DRP1) proteins in a rabbit model of diabetes-induced atrial remodelling [137]. PGZ had similar effects in trisomic fetal fibroblasts where OPA1 and MFN1 gene expression was restored and DRP1 inhibited [138]. Pretreatment with PGZ (20 nmol) resulted in a reduction in DRP1-pS616 in the hippocampus following transient global ischaemia, which correlated with a reduction in oxidative stress and cell death [139]. On postnatal day 5 rat model of neonatal inflammation-induced brain injury, (mimicking preterm neuroinflammation), PGZ (20
mg/kg) reduced white matter damage and restored mitochondrial function [140]. Although PGZ is not routinely used in paediatric patients, small studies have shown no adverse effects in children [141] and adolescents [142], 60 mg daily, equivalent to approx. 2.4 mg/kg). However, neonatal HIE would only require treatment for a short period and higher doses may therefore be feasible.

**Melatonin**

Although considered a dietary supplement and therefore not regulated in the United States, Melatonin is indicated for use in Europe and the United Kingdom for insomnia. Melatonin is a naturally occurring hormone that regulates circadian rhythm and coincidentally is currently in clinical trials for neonatal HI injury [143]. As well as its antioxidant properties, Melatonin is reported to protect OPA1-mediated mitochondrial fusion in models of myocardial I/R injury [144,145], vascular calcification [146], diabetic fatty kidneys [147] and MCAO [148] most commonly via activation of AMPK.

**Tolfenamic acid**

Tolfenamic acid is an anti-inflammatory, cyclooxygenase-2 inhibitor, which is in clinical use for treatment of acute migraine [149] and is also being investigated for efficacy in neurodegenerative conditions such as Alzheimer’s disease [150] and Huntington’s disease [151]. However, it was recently identified in a yeast-based screen of FDA-approved small molecules to rescue loss-of-function mutations in OPA1 that lead to dominant optic atrophy [152]. In patient fibroblasts harbouring mutations in OPA1, Tolfenamic acid restored mitochondrial morphology, mildly enhanced ATP synthesis and decreased ROS production [152]. Interestingly, previous molecular analysis identified CDK5 inhibition as a target for tolfenamic acid [153]. As CDK5 phosphorylates Drp1, it is possible that tolfenamic acid inhibits DRP1-mediated fission rather than acting directly on OPA1.

**Summary**

Brain injury in the neonatal brain occurring around the time of birth leads to life-long neurological impairment and there is a clear unmet need for additional therapies to supplement or replace the use of therapeutic hypothermia. Mitochondria in neurons are vulnerable to the pathological effects of HI, both in the neonatal and the adult brain and the insult can trigger intrinsic apoptosis (via Bax-mediated MOMP) as well as perturbations of mitochondrial dynamics. As the molecular players driving the balanced actions of mitochondrial fission and fusion become more defined, specific interventions targeting these pathways for therapeutic benefit become more realistic. Repurposing drugs already in clinical use may offer a rapid and cost-effective route through to new treatments for neonatal HIE.

**Competing Interests**
The authors declare that there are no competing interests associated with the manuscript.

**Funding**

This work was supported by the King’s College London, MRC Doctoral Training Partnership in Biomedical Sciences [grant number MR/N013700/1 (to A.J.)]; and the Medical Research Council New Investigator Award [grant number MR/T014725/1 (to C.T.)].

**Open Access**

Open access for this article was enabled by the participation of Royal Veterinary College in an all-inclusive Read & Publish agreement with Portland Press and the Biochemical Society under a transformative agreement with JISC.

**Abbreviations**

AIF, apoptosis-inducing factor; AKAP, A-kinase anchoring protein; AMPK, AMP-activated protein kinase; Drp, dynamin-related protein; FIS1, Fission 1; HI, hypoxic–ischaemic; HIE, hypoxic–ischaemic encephalopathy; IMM, inner mitochondrial membrane; I/R, ischaemia–reperfusion; L-OPA1, long optic atrophy 1; MCAO, middle cerebral artery occlusion; MFF, mitochondrial fission factor; MFN, mitofusin; MID, mitochondrial division; MPP, mitochondrial processing peptidase; mtDNA, mitochondrial DNA; OMM, outer mitochondrial membrane; OPA1, optic atrophy 1; PGZ, Pioglitazone; PINK, PTEN-induced serine/threonine kinase; PKA, Protein Kinase A; ROS, reactive oxygen species; S-OPA1, short optic atrophy 1; Δψm, membrane potential.
References

1. Steiner, P. (2019) Brain fuel utilization in the developing brain. *Ann. Nutr. Metab.* **75**, 8–18, https://doi.org/10.1159/000508054

2. Andreux, P., Chevillard, C., Cunha-Neto, E. and Nunes, J.P.S. (2021) Mitochondria as a cellular hub in infection and inflammation. *Int. J. Mol. Sci.* **22**, 11338, https://doi.org/10.3390/ijms22111338

3. Godoy, J.A., Rios, J.A., Picon-Pages, P., Herrera-Fernandez, V., Swaby, B., Crepin, G. et al. (2021) Mitostasis, calcium and free radicals in health, aging and neurodegeneration. *Biomolecules* **11**, 1012, https://doi.org/10.3390/biom11071012

4. Dadsena, S., King, L.E. and García-Sáez, A.J. (2021) Apoptosis regulation at the mitochondria membrane level. *Biochim. Biophys. Acta Biomembr.* **1863**, 183716, https://doi.org/10.1016/j.bbamem.2021.183716

5. Sprenger, H.G. and Langer, T. (2019) The good and the bad of mitochondrial breakups. *Trends Cell Biol.* **29**, 888–900, https://doi.org/10.1016/j.tcb.2019.08.003

6. Yapa, N.M.B., Lisnyak, V., Reljic, B. and Ryan, M.T. (2021) Mitochondrial dynamics in health and disease. *FEBS Lett.* **595**, 1184–1204, https://doi.org/10.1002/1873-3468.14077

7. Cirigno, L., Muglia, M., Quattrell, A., Spadafora, P., Cavalcanti, F., Pioggia, G. et al. (2020) The mitochondrial dysfunction hypothesis in autism spectrum disorders: current status and future perspectives. *Int. J. Mol. Sci.* **21**, 5785, https://doi.org/10.3390/ijms21165785

8. Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G.P., Bresolin, N. and Masliah, E. (2020) The role of mitochondria in neurodegenerative diseases: the lesson from Alzheimer’s disease and Parkinson’s disease. *Mol. Neurobiol.* **57**, 2959–2980, https://doi.org/10.1007/s12035-020-01926-1

9. Vongsfak, J., Apaijai, N., Vaniyapong, T., Chattipakorn, N. and Chattipakorn, S.C. (2021) The alterations in mitochondrial dynamics following cerebral ischemia/reperfusion injury. *Antioxidants (Basel)* **10**, 1384, https://doi.org/10.3390/antiox10091384

10. Gajavelli, S., Sinha, V.K., Mazzeo, A.T., Spurlock, M.S., Lee, S.W., Ahmed, A.I. et al. (2015) Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury. *J. Bioenerg. Biomembr.* **47**, 133–148, https://doi.org/10.1007/s10863-014-9599-1

11. Kim, Y., Vadodaria, K.C., Lenkei, Z., Kato, T., Gage, F.H., Marchetto, M.C. et al. (2019) Mitochondria, metabolism, and redox mechanisms in psychiatric disorders. *Antioxid. Redox Signal.* **31**, 275–317, https://doi.org/10.1089/ars.2018.7606

12. Popov, L.D. (2020) Mitochondrial biogenesis: an update. *J. Cell. Mol. Med.* **24**, 4892–4899, https://doi.org/10.1111/jcmm.15194

13. Palikaras, K., Lissaki, E. and Tavernarakis, N. (2018) Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. *Nat. Cell Biol.* **20**, 1013–1022, https://doi.org/10.1038/s41456-018-0176-2

14. Mandai, A. and Dreyer, C.M. (2019) Axonal transport and mitochondrial function in neurons. *Front. Cell Neurosci.* **13**, 373, https://doi.org/10.3389/fncel.2019.00373

15. Yuile, R.J. and van der Bliek, A.M. (2012) Mitochondrial fission, fusion, and stress. *Science* **337**, 1062–1065, https://doi.org/10.1126/science.1219855

16. Yao, C.H., Wang, R., Wang, Y., Kung, C.P., Weber, J.D. and Patti, G.J. (2019) Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. *eLife* **8**, e41351, https://doi.org/10.7554/eLife.41351

17. Gottlieb, R.A. and Bernstein, D. (2016) Mitochondrial remodeling: rearranging, recycling, and reprogramming. *Cell Calcium* **60**, 88–101, https://doi.org/10.1016/j.ceca.2016.04.006

18. Wai, T. and Langer, T. (2016) Mitochondrial dynamics and metabolic regulation. *Trends Endocrinol. Metab.* **27**, 105–117, https://doi.org/10.1016/j.tem.2015.12.001

19. Yan, L., Qi, Y., Ricketson, D., Li, L., Subramanian, K., Zhao, J. et al. (2020) Structural analysis of a trimeric assembly of the mitochondrial dynamin-like GTPase Mgm1. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 4061–4070, https://doi.org/10.1073/pnas.1919116117

20. Sun, Y., Xue, W., Song, Z., Huang, K. and Zheng, L. (2015) Restoration of Opa1-long isoform inhibits retinal injury-induced neurodegeneration. *Cell Rep.* **15**, 343–354, https://doi.org/10.1016/j.celrep.2015.01.1359-y

21. Song, Z., Chen, H., Fiket, M., Alexander, C. and Chan, D.C. (2007) OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. *J. Cell Biol.* **178**, 749–755, https://doi.org/10.1083/jcb.200704110

22. Ishihara, N., Fujita, Y., Oka, T. and Mihara, K. (2006) Regulation of mitochondrial morphology through proteolytic cleavage of OPA1. *EMBO J.* **25**, 2966–2977, https://doi.org/10.1038/sj.emboj.7601184

23. Guillery, O., Mallá, F., Landes, T., Guillou, E., Blackstone, C., Lombes, A. et al. (2008) Metalloproteinase-mediated OPA1 processing is modulated by the mitochondrial membrane potential. *Biol. Cell* **100**, 315–325, https://doi.org/10.1042/BC20070110

24. Olichon, A., Elachouri, G., Baricault, L., Delettre, C., Belenguer, P. and Lenaers, G. (2007) OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. *Cell Death Differ.* **14**, 682–692, https://doi.org/10.1038/sj.jdd.4402048

25. Ban, T., Ishihara, T., Kohn, H., Salta, S., Ichimura, A., Maenaka, K. et al. (2017) Molecular basis of selective mitochondrial fusion by heterotypic action between OPA1 and cardiolipin. *Nat. Cell Biol.* **19**, 856–863, https://doi.org/10.1038/nccb3560

26. Civiletto, G., Varanita, T., Cerutti, R., Gorletta, T., Barbaro, S., Marchet, S. et al. (2015) OPA1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models. *Cell Metab.* **21**, 845–854, https://doi.org/10.1016/j.cmet.2015.04.016

27. Kushnareva, Y., Seong, Y., Andreyev, A.Y., Kuwana, T., Kiosses, W.B., Votruba, M. et al. (2016) Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency. *Cell Death Dis.* **7**, e2309, https://doi.org/10.1038/cddis.2016.160

28. Varanita, T., Soriano, M.E., Romanelli, V., Zaglia, T., Quintana-Cabrera, R., Semenzato, M. et al. (2015) The OPA1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage. *Cell Metab.* **21**, 834–844, https://doi.org/10.1016/j.cmet.2015.05.007

29. Tilokani, L., Nagashima, S., Paupe, V. and Prudent, J. (2018) Mitochondrial dynamics: overview of molecular mechanisms. *Essays Biochem.* **62**, 341–360, https://doi.org/10.1042/EBC20170104
30 Adaniya, S.M., J., O.U., Cypress, M.W., Kusakari, Y. and Jhun, B.S. (2019) Posttranslational modifications of mitochondrial fission and fusion proteins in cardiac physiology and pathophysiology. Am. J. Physiol. Cell Physiol. 316, C583–C604, https://doi.org/10.1152/ajpcell.00523.2018
31 Escobar-Henriques, M. and Joaquim, M. (2019) Mitofusins: disease gatekeepers and hubs in mitochondrial quality control by E3 ligases. Front. Physiol. 10, 517, https://doi.org/10.3389/fphys.2019.00517
32 Gegg, M.E., Cooper, J.M., Chau, K.T., Rojo, M.; Schapira, A.H. and Taanman, J.W. (2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum. Mol. Genet. 19, 4861–4870, https://doi.org/10.1093/hmg/ddq419
33 Chen, Y. and Dorn, II, G.W. (2013) PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340, 471–475, https://doi.org/10.1126/science.1231031
34 Karbowski, M., Neutner, A. and Youle, R.J. (2007) The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J. Cell Biol. 178, 71–84, https://doi.org/10.1083/jcb.20061064
35 Pyakurel, A., Savoia, C., Hess, D. and Scorrano, L. (2015) Extracellular regulated kinase phosphorylates mitofusin 1 to control mitochondrial morphology and apoptosis. Mol. Cell 58, 244–254, https://doi.org/10.1016/j.molcel.2015.02.021
36 Cook, S.J., Stuart, K., Gilley, R. and Sale, M.J. (2017) Control of cell death and mitochondrial fusion by ERK1/2 MAP kinase signalling. FEBS J. 284, 4177–4195, https://doi.org/10.1111/febs.14122
37 Ishihara, N., Eura, Y. and Mihara, K. (2004) Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J. Cell Sci. 117, 6535–6546, https://doi.org/10.1242/jcs.01565
38 Santel, A., Frank, S., Gaume, B., Herrier, M., Youle, R.J. and Fuller, M.T. (2003) Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells. J. Cell Sci. 116, 2763–2774, https://doi.org/10.1242/jcs.00479
39 de Brito, O.M. and Scorrano, L. (2008) Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605–610, https://doi.org/10.1038/nature07534
40 Chen, H., McCaffery, J.M. and Chan, D.C. (2007) Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130, 548–562, https://doi.org/10.1016/j.cell.2007.06.026
41 Filadi, R., Pendin, D. and Pizzo, P. (2018) Mitofusin 2: from functions to disease. Cell Death Dis. 9, 330, https://doi.org/10.1038/s41419-017-0023-6
42 Friedman, J.R., Lackner, L.L., West, M., DiBenedetto, J.R., Nunnari, J. and Voeltz, G.K. (2011) ER tubules mark sites of mitochondrial division. Science 334, 358–362, https://doi.org/10.1126/science.1207385
43 Anand, R., Wai, T., Baker, M.J., Kladt, N., Schauss, A.C., Rugarli, E. et al. (2014) The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. J. Cell Biol. 204, 919–929, https://doi.org/10.1083/jcb.201308006
44 Korwitz, A., Merkwirth, C., Richter-Dennerlein, R., Troder, S.E., Sprenger, H.G., Quiros, P.M. et al. (2016) Loss of OMA1 delays neurodegeneration by preventing stress-induced OPA1 processing in mitochondria. J. Cell Biol. 212, 157–166, https://doi.org/10.1083/jcb.201507022
45 Mears, J.A., Lackner, L.L., Fang, S., Ingerman, E., Nunnari, J. and Hinshaw, J.E. (2011) Conformational changes in Dnm1 support a contractile mechanism for mitochondrial fission. Nat. Struct. Mol. Biol. 18, 20–26, https://doi.org/10.1038/nsmb.1949
46 Filippo, K.H., Gnanasekaran, A., Perkins, G.A., Ahmad, A., Merrill, R.A., Dickey, A.S. et al. (2018) AKAP1 protects from cerebral ischemic stroke by inhibiting Drp1-dependent mitochondrial fission. J. Neurosci. 38, 8233–8242, https://doi.org/10.1523/JNEUROSCI.10649-18.2018
47 Gui, C., Ren, Y., Chen, J., Wu, X., Mao, K., Li, H. et al. (2020) p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant AS3T alpha-synuclein model of Parkinson’s disease. Toxicol. Appl. Pharmacol. 388, 114874, https://doi.org/10.1016/j.taap.2019.114874
48 Zhou, L., Zhang, Q., Zhang, P., Sun, L., Peng, C., Yuan, Z. et al. (2017) c-Abl-mediated Drp1 phosphorylation promotes oxidative stress-induced mitochondrial fragmentation and neuronal cell death. Cell Death Dis. 8, e3117, https://doi.org/10.1038/cddis.2017.524
49 Wikstrom, J.D., Israels, T., Bachar-Wikstrom, E., Swissa, A., Ariav, Y., Wais, M. et al. (2013) AMPK regulates ER morphology and function in stressed pancreatic beta-cells via phosphorylation of DRP1. Mol. Endocrinol. 27, 1706–1723, https://doi.org/10.1210/me.2013-1109
50 Tsushima, K., Buggler, H., Wende, A.R., Solo, J., Jenson, G.A., Tor, A.R. et al. (2018) Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission. Circ. Res. 122, 58–73, https://doi.org/10.1161/CIRCRESAHA.117.311307
51 Chang, C.R. and Blackstone, C. (2007) Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J. Biol. Chem. 282, 21583–21587, https://doi.org/10.1074/jbc.C700083200
52 Pfluger, P.T., Kabra, D.G., Aichler, M., Schriever, S.C., Pfuhlmann, K., Garcia, V.C. et al. (2015) Calcineurin links mitochondrial elongation with energy metabolism. Cell Metab. 22, 838–850, https://doi.org/10.1016/j.cmet.2015.06.022
53 Cribs, J.T. and Strack, S. (2007) Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep. 8, 939–944, https://doi.org/10.1038/sj.embor.7401062
54 Merrill, R.A., Dagda, R.K., Dickey, A.S., Cribs, J.T., Green, S.H., Usachev, Y.M. et al. (2011) Mechanism of neuroprotective mitochondrial remodeling by PAK1/AKAP1. PLoS Biol. 9, e1000612, https://doi.org/10.1371/journal.pbio.1000612
55 Oettinghaus, B., D’Alonzo, D., Barbieri, E., Restelli, L.M., Savoia, C., Licci, M. et al. (2016) DRP1-dependent apoptotic mitochondrial fission occurs independently of Mff and Fis1 in Drp1 recruitment and are specific for mitochondrial fission. J. Biol. Chem. 288, 27584–27593, https://doi.org/10.1074/jbc.M114789873
56 Palmer, C.S., Elgass, L.D., Parton, R.G., Osellame, L.D., Stojarovski, D. and Ryan, M.T. (2013) Adaptor proteins MID49 and MID51 can act independently of Mff and Fis1 in Drp1 recruitment and are specific for mitochondrial fission. J. Biol. Chem. 288, 27584–27593, https://doi.org/10.1074/jbc.M114789873
57 Kraus, F. and Ryan, M.T. (2017) The constriction and scission machineries involved in mitochondrial fission. J. Cell Sci. 130, 2953–2960, https://doi.org/10.1242/jcs.199562

© 2022 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Toyama, E.O., Herzig, S., Crouchet, J., Lewis, J.T.L., Loson, O.C., Hellberg, K. et al. (2016) AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275–281, https://doi.org/10.1126/science.aab4138

Seabright, A.P., Fine, N.H.F., Barlow, J.P., Lord, S.D., Musa, I., Gray, A. et al. (2020) AMPK activation induces mitophagy and promotes mitochondrial fission while activating TBK1 in a PINK1–Parkin independent manner. FASEB J. 34, 628–6301, https://doi.org/10.1096/fj.201903051R

Yu, R., Jin, S.B., Lendahl, U., Nister, M. and Zhao, J. (2019) Human Fis1 regulates mitochondrial dynamics through inhibition of the fusion machinery. EMBO J. 38, e9748, https://doi.org/10.15252/embj.20189748

Loson, O.C., Song, Z., Chen, H. and Chan, D.C. (2013) Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol. Biol. Cell 24, 659–667, https://doi.org/10.1091/mbc.e12-10-0721

Zhao, J., Liu, T., Jin, S., Wang, X., Gu, M., Uhlen, P. et al. (2011) Human MIEF1 recruits Drp1 to mitochondrial outer membranes. EMBO J. 30, 2762–2778, https://doi.org/10.1038/embj.2011.198

Ma, K., Chen, G., Li, W., Kepp, O., Zhu, Y. and Chen, Q. (2020) Mitophagy. mitochondrial homeostasis, and cell fate. Front. Cell Dev. Biol. 8, 467, https://doi.org/10.3389/fcell.2020.00467

Youle, R.J. and Narendra, D.P. (2011) Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9–14, https://doi.org/10.1038/nrm3028

Narendra, D.P. and Youle, R.J. (2011) Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid. Redox Sign. 14, 1929–1938, https://doi.org/10.1089/ars.2010.3799

Liu, L., Feng, D., Chen, G., Chen, M., Zheng, Q., Song, P. et al. (2012) Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 14, 177–185, https://doi.org/10.1038/ncb2422

Ventura-Clapier, R., Garnier, A. and Vekslar, V. (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc. Res. 79, 208–217, https://doi.org/10.1093/cvr/cvm098

Kleele, T., Rey, T., Winter, J., Zaganelli, S., Mahecic, D., Perretten Lambert, H. et al. (2021) Distinct fission signatures predict mitochondrial degradation or biogenesis. Nature 593, 435–439, https://doi.org/10.1038/s41586-021-03510-6

Pickles, S., Vigie, P. and Youle, R.J. (2018) Mitophagy and quality control mechanisms in mitochondrial maintenance. Curr. Biol. 28, R170–R185, https://doi.org/10.1016/j.cub.2018.01.004

Harper, J.W., Ordureau, A. and Heo, J.M. (2018) Building and decoding ubiquitin chains for mitophagy. Nat. Rev. Mol. Cell Biol. 19, 93–108, https://doi.org/10.1038/nrm.2017.129

Scarpulla, R.C., Vega, R.B. and Kelly, D.P. (2012) Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol. Metab. 23, 459–466, https://doi.org/10.1016/j.tem.2012.06.006

Krishnan, V., Kumar, V., Variane, G.F.T., Carlo, W.A., Bhutta, Z.A., Sizonenko, S. et al. (2021) Need for more evidence in the prevention and management of perinatal asphyxia and neonatal encephalopathy in low and middle-income countries: A call for action. Semin. Fetal Neonatal Med. 26, 101271, https://doi.org/10.1016/j.siny.2021.101271

Rocha-Ferreira, E. and Hristova, M. (2016) Plasticity in the neonatal brain following hypoxic-ischaemic injury. Neural Plast. 2016, 4901014, https://doi.org/10.1155/2016/4901014

Vannucci, R.C. and Perlman, J.M. (1997) Interventions for perinatal hypoxic–ischemic encephalopathy. Pediatr. Res. 41, 1004, https://doi.org/10.1542/peds.100.6.1004

Northington, F., Ferriero, D.M., Flock, D.L. and Martin, L.J. (2001) Delayed neurodegeneration in neonatal rat thalamus after hypoxia–ischemia is apoptosis. J. Neurosci. 21, 1931–1938, https://doi.org/10.1523/JNEUROSCI.21-06-01931.2001

Thorton, C., Leav, B., Mailard, C., Nair, S., Jinnai, M. and Hagberg, H. (2017) Cell death in the developing brain after hypoxia-ischemia. Front. Cell Neurosci. 11, 248, https://doi.org/10.3389/fncel.2017.00248

Thorton, C. and Hagberg, H. (2015) Role of mitochondria in apoptotic and necroptotic cell death in the developing brain. Clin. Chim. Acta 451, 35–38, https://doi.org/10.1016/j.cca.2015.01.026

Baburamani, A.A., Hurling, C., Stolp, H., Sobottka, K., Gressens, P., Hagberg, H. et al. (2015) Mitochondrial optic atrophy (OPA) 1 processing is altered in response to neonatal hypoxic-ischemic brain injury. Int. J. Mol. Sci. 16, 22509–22526, https://doi.org/10.3390/ijms160922509

Feilis, B. and Gressens, P. (2012) Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol. 11, 556–566, https://doi.org/10.1016/S1474-4422(12)70058-3

Graham, E.M., Ruis, K.A., Hartman, A.L., Northington, F.J. and Fox, H.E. (2008) A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am. J. Obstet. Gynecol. 199, 587–595, https://doi.org/10.1016/j.ajog.2008.06.094

Laptop, A.R., Shankaran, S., Tyson, J.E., Munoz, B., Bell, E.F., Goldberg, R.N. et al. (2017) Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial. JAMA 318, 1550–1560, https://doi.org/10.1001/jama.2017.14972

Shankaran, S., Papas, A., McDonald, S.A., Vohr, B.R., Hintz, S.R., Yolton, K. et al. (2012) Childhood outcomes after hypothermia for neonatal encephalopathy. N. Engl. J. Med. 366, 2085–2092, https://doi.org/10.1056/NEJMoa1112060

Shankaran, S., Laptop, A.R., Ehrenkranz, R.A., Tyson, J.E., McDonald, S.A., Donovon, E.F. et al. (2005) Whole-body hypothermia for neonates with hypoxic–ischemic encephalopathy. N. Engl. J. Med. 353, 1574–1584, https://doi.org/10.1056/NEJMcp050929

Guillet, R., Edwards, A.D., Thoresen, M., Ferriero, D.M., Gluckman, P.D., Whitelaw, A. et al. (2012) Seven- to eight-year follow-up of the CoolCap trial of head cooling for neonatal encephalopathy. Pediatr. Res. 71, 205–209, https://doi.org/10.1038/pr.2011.30

Azizpouri, D., Strohm, B., Marlow, N., Brocklehurst, P., Deierl, A., Eddama, O. et al. (2014) Effects of hypothermia for perinatal asphyxia on childhood outcomes. N. Engl. J. Med. 371, 140–149, https://doi.org/10.1056/NEJMoa1315788

Edwards, A.D., Brocklehurst, P., Gunn, A.J., Halliday, H., Juszczak, E., Levene, M. et al. (2010) Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 340, c363, https://doi.org/10.1136/bmj.c363
88 Anne Stetler, R., Leak, R.K., Gao, Y. and Chen, J. (2013) The dynamics of the mitochondrial organelle as a potential therapeutic target. J. Cereb. Blood Flow Metab. 33, 22–32, https://doi.org/10.1038/jcbfm.2013.158

89 Hagberg, H., Thornberg, E., Blennow, M., Kjellmer, I., Lagercrantz, H., Thiringer, K. et al. (1993) Excitatory amino acids in the cerebrospinal fluid of asphyxiated infants: relationship to hypoxic-ischemic encephalopathy. Acta Paediatr. 82, 925–929, https://doi.org/10.1111/1651-2227.1993.tb16001.x

90 Puka-Sundvall, M., Gajkowska, B., Cholewinski, M., Blomgren, K., Lazarewicz, J.W. and Hagberg, H. (2000) Subcellular distribution of calcium and ultrastructural changes after cerebral hypoxia-ischemia in immature rats. Brain Res. Dev. Brain Res. 125, 31–41, https://doi.org/10.1016/S0165-3806(00)01103-0

91 van den Tweel, E.R., Nijboer, C., Kavelaars, A., Heijnen, C.J., Groenendaal, F. and van Bel, F. (2005) Expression of nitric oxide synthase isoforms and nitrotyrosine formation after hypoxia-ischemia in the neonatal rat brain. J. Neuroimmunol. 167, 64–71, https://doi.org/10.1016/j.jneuroim.2005.06.031

92 Wallin, C., Puka-Sundvall, M., Hagberg, H., Weber, S.G. and Sandberg, M. (2000) Alterations in glutathione and amino acid concentrations after hypoxia-ischemia in the immature rat brain. Brain Res. Dev. Brain Res. 125, 51–60, https://doi.org/10.1016/S0165-3806(00)01112-7

93 Northington, F.J., Zelaya, M.E., O’Riordan, D.P., Blomgren, K., Flock, D.L., Hagberg, H. et al. (2007) Failure to complete apoptosis following neonatal hypoxia-ischemia manifests as “continuum” phenotype of cell death and occurs with multiple manifestations of mitochondrial dysfunction in rodent forebrain. Neuroscience 149, 822–833, https://doi.org/10.1016/j.neuroscience.2007.06.060

94 Puka-Sundvall, M., Gajkowska, B., Cholewinski, M., Blomgren, K., Lazarewicz, J.W., Rousset, C.I. et al. (2012) Molecular mechanisms of neonatal brain injury. Neurotol. Res. Int. 2012, 506320, https://doi.org/10.1155/2012/506320

95 Gilland, E., Puka-Sundvall, M., Haller, M. and Hagberg, H. (1998) Mitochondrial function and energy metabolism after hypoxia-ischemia in immature rat brain: involvement of NMDA-receptors. J. Cereb. Blood Flow Metab. 18, 297–304, https://doi.org/10.1097/00004647-199803000-00008

96 Wang, Y., Liu, Q., Cai, J., Wu, P., Wang, D., Shi, Y. et al. (2022) Emodin prevents renal ischemia-reperfusion injury via suppression of CAMKII/DRP1-mediated mitochondrial fission. Eur. J. Pharmacol. 916, 174603, https://doi.org/10.1016/j.ejphar.2021.174603

97 Gilland, E., Puka-Sundvall, M., Haller, M. and Hagberg, H. (1998) Mitochondrial function and energy metabolism after hypoxia-ischemia in immature rat brain: involvement of NMDA-receptors. J. Cereb. Blood Flow Metab. 18, 297–304, https://doi.org/10.1097/00004647-199803000-00008

98 Wang, X., Han, W., Du, X., Zhu, C., Carlsson, Y., Baburamani, A.A. et al. (2012) Molecular mechanisms of neonatal brain injury. Mol. Med. 7, 629–646, https://doi.org/10.1038/nrneph.2017.107

99 Rosenberg, A.A., Parks, J.K., Murdaugh, E. and Parker, Jr. W.D. (1989) Mitochondrial function after asphyxia in newborn lambs. Stroke 20, 674–679, https://doi.org/10.1161/01.STR.20.5.674

100 Zhu, C., Wang, X., Huang, Z., Qiu, L., Xu, P., Vahsen, N. et al. (2007) Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ. 14, 775–784, https://doi.org/10.1038/sj.cdd.4402053

101 Wang, X., Carlsson, Y., Basso, E., Zhu, C., Rousset, C.I., Rasola, A. et al. (2009) Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J. Neurosci. 29, 2588–2596, https://doi.org/10.1523/JNEUROSCI.5832-08.2009

102 Gibson, M.E., Han, B.H., Chae, J., Knudson, C.M., Korsmeyer, S.J., Parsadanian, M. et al. (2001) BAX contributes to apoptotic-like death following neonatal hypoxia-ischemia: evidence for distinct apoptosis pathways. Mol. Med. 7, 644–655, https://doi.org/10.1007/BF03401871

103 Wang, X., Han, W., Du, X., Zhu, C., Carlsson, Y., Mallard, C. et al. (2010) Neuroprotective effect of Bax-protective peptide on neonatal brain injury. Stroke 41, 2061–2065, https://doi.org/10.1161/STROKEAHA.110.589051

104 Bhargava, P. and Schnellmann, R.G. (2017) Mitochondrial energetics in the kidney. Nat. Rev. Nephrol. 13, 629–646, https://doi.org/10.1038/nrneph.2017.107

105 Forte, M., Schirole, L., Amei, P., Basso, C., Catalucci, D., Modica, J. et al. (2021) The role of mitochondrial dynamics in cardiovascular diseases. Br. J. Pharmacol. 178, 2060–2076, https://doi.org/10.1111/bph.15068

106 Wang, Y., Liu, Q., Cai, J., Wu, P., Wang, D., Shi, Y. et al. (2022) Emodin prevents renal ischemia-reperfusion injury via suppression of CAMKII/DRP1-mediated mitochondrial fission. Eur. J. Pharmacol. 916, 174603, https://doi.org/10.1016/j.ejphar.2021.174603

107 Bouche, L., Kamekura, O., Tamae, H., Garcia, G., Villedieu, C., Pilott, B. et al. (2021) DRP1 haploinsufficiency attenuates cardiac ischemia/reperfusion injuries. PLoS ONE 4, e0248554, https://doi.org/10.1371/journal.pone.0248554

108 Hall, A.R., Burke, N., Dongworth, R.K., Kalkhoran, S.B., Vicencio, J.M. et al. (2016) Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction. Cell Death Dis. 7, e2383, https://doi.org/10.1038/cddis.2016.139

109 Yang, J.L., Mukda, S. and Chen, S.D. (2018) Diverse roles of mitochondria in ischemic stroke. Redox Biol. 16, 263–275, https://doi.org/10.1016/j.redox.2018.03.002

110 Gröhn, J., Kim, S.W., Mamrak, U., Tobaben, S., Cassidy-Stone, A., Nunnari, J. et al. (2012) Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ. 19, 1446–1458, https://doi.org/10.1038/cdd.2012.18

111 Kumar, R., Bukowski, M.J., Wider, J.M., Reynolds, C.A., Calo, L., Lepore, B. et al. (2016) Mitochondrial dynamics following global cerebral ischemia. Mol. Cell. Neurosci. 76, 68–75, https://doi.org/10.1016/j.mcn.2016.08.010

112 Zhou, K., Wu, J., Cheng, J., Zhou, Y., Chen, X., Wu, Q. et al. (2019) Schaftoside ameliorates oxygen glucose deprivation-induced inflammation associated with the TLR4/MyD88/Drp1-related mitochondrial fission in BV2 microglia cells. J. Pharmacol. Sci. 139, 15–22, https://doi.org/10.1016/j.jpns.2018.10.012

113 Li, Y., Wang, M. and Wang, S. (2016) Effect of inhibiting mitochondrial fission on energy metabolism in rat hippocampal neurons during ischemia/reperfusion injury. Neurol. Res. 38, 1027–1034, https://doi.org/10.1080/01616412.2016.1215050
129 Pellattiero, A. and Scorrano, L. (2018) Flaming mitochondria: the anti-inflammatory drug leflunomide boosts mitofusins. *Cell Chem Biol*. 25, 231–233, https://doi.org/10.1016/j.chembiol.2018.02.014

130 Humphries, B.A., Cutler, A.C., Buschhau, J.M., Chen, Y.C., Oyli, T., Palagama, D.S.W. et al. (2020) Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer. *Breast Cancer Res*. 22, 60, https://doi.org/10.1186/s13058-020-01301-x

131 Karaman, A., Turkmen, E., Gursul, C., Tas, E. and Fadillioglu, E. (2006) Prevention of renal ischemia/reperfusion injury in rats by leflunomide. *Int. J. Urol*. 13, 1434–1441, https://doi.org/10.1111/j.1442-2440.2006.01592.x

132 Baban, B., Liu, J.Y. and Mozaffari, M.S. (2012) Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Treg signaling and metastasis in triple-negative breast cancer. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 303, R1136–R1146, https://doi.org/10.1152/ajpregu.00315.2012

133 Yildiz, Y., Kose, H., Cecen, S., Ergin, K., Demir, E.M. and Serter, M. (2010) Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion injury. *Dig. Dis. Sci.* 55, 245–252, https://doi.org/10.1007/s10620-009-0737-0

134 Karaman, A., Fadillioglu, E., Turkmen, E., Tas, E. and Yilmaz, Z. (2006) Protective effects of leflunomide against intestinal ischemia-reperfusion injury of the rat liver. *Pediatr. Surg. Int.* 22, 428–434, https://doi.org/10.1007/s00383-006-1668-x

135 Rosenstock, J., Einhorn, D., Hershon, K., Glazer, N.B. and Yu, S. (2002) Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. *Int. J. Clin. Pract.* 56, 251–257

136 Corona, J.C. and Duchen, M.R. (2016) PPARgamma as a therapeutic target to rescue mitochondrial function in neurological disease. *Free Radic. Biol. Med.* 100, 153–163, https://doi.org/10.1016/j.freeradbiomed.2016.06.023

137 Zhang, Z., Zhang, X., Meng, L., Gong, M., Li, J., Shi, W. et al. (2021) Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis, dynamics, and function through the PPAR-gamma/PGC-1alpha signaling pathway. *Front. Pharmacol.* 12, 658362, https://doi.org/10.3389/fphar.2021.658362

138 Mollo, N., Nitti, M., Zerillo, L., Faicchia, D., Micillo, T., Accarino, R. et al. (2019) Pioglitazone improves mitochondrial organization and bioenergetics in Down syndrome cells. *Front. Genet.* 10, https://doi.org/10.3389/fgene.2019.00606

139 Huang, Y.C., Lin, T.K., Yang, D.I., Yang, J.L., Lou, C.W. and Chen, S.D. (2016) Peroxisome proliferator-activated receptor-gamma dependent pathway reduces the phosphorylation of dynamin-related protein 1 and ameliorates hippocampal injury induced by global ischemia in rats. *J. Biomed. Sci.* 23, 44, https://doi.org/10.1007/s10232-016-0262-3

140 Yeh, J.H., Wang, K.C., Kaizaki, A., Lee, J.W., Wei, H.C., Tucci, M.A. et al. (2021) Pioglitazone ameliorates lipopolysaccharide-induced behavioral impairment, brain inflammation, white matter injury and mitochondrial dysfunction in neonatal rats. *Int. J. Mol. Sci.* 22, 6306, https://doi.org/10.3390/ijms22126306
141 Boris, M., Kaiser, C.C., Goldblatt, A., Elice, M.W., Edelson, S.M., Adams, J.B. et al. (2007) Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflammation 4, 3, https://doi.org/10.1186/1742-2094-4-3

142 Zdravkovic, V., Hamilton, J.K., Daneman, D. and Cummings, E.A. (2006) Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J. Pediatr. 149, 845–849, https://doi.org/10.1016/j.jpeds.2006.08.049

143 Ahmed, J., Pullattayil, S.A., Robertson, N.J. and More, K. (2021) Melatonin for neuroprotection in neonatal encephalopathy: A systematic review & meta-analysis of clinical trials. Eur. J. Paediatr. Neuro. 31, 38–45, https://doi.org/10.1016/j.ejpn.2021.02.003

144 Zhang, Y., Wang, Y., Xu, J., Tian, F., Hu, S., Chen, Y. et al. (2019) Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways. J. Pineal Res. 66, e12542, https://doi.org/10.1111/jpi.12542

145 Qi, X. and Wang, J. (2020) Melatonin improves mitochondrial biogenesis through the AMPK/PGC1alpha pathway to attenuate ischemia/reperfusion-induced myocardial damage. Aging (Albany N.Y.) 12, 7299–7312, https://doi.org/10.18632/aging.103078

146 Chen, W.R., Zhou, Y.J., Yang, J.Q., Liu, F., Wu, X.P. and Sha, Y. (2020) Melatonin attenuates calcium deposition from vascular smooth muscle cells by activating mitochondrial fusion and mitophagy via an AMPK/OPA1 signaling pathway. Oxid. Med. Cell. Longev. 2020, 5298483, https://doi.org/10.1155/2020/5298483

147 Agil, A., Chayah, M., Visiedo, L., Navarro-Alarcon, M., Rodriguez Ferrer, J.M., Tassi, M. et al. (2020) Melatonin improves mitochondrial dynamics and function in the kidney of Zucker diabetic fatty rats. J. Clin. Med. 9, 2916, https://doi.org/10.3390/jcm9092916

148 Wei, N., Pu, Y., Yang, Z., Pan, Y. and Liu, L. (2019) Therapeutic effects of melatonin on cerebral ischemia reperfusion injury: Role of Yap-OPA1 signaling pathway and mitochondrial fusion. Biomed. Pharmacother. 110, 203–212, https://doi.org/10.1016/j.biopha.2018.11.060

149 Hansen, P.E. (1994) Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol. Toxicol. 75, 81–82, https://doi.org/10.1111/j.1600-0773.1994.tb02005.x

150 Zhang, H., Wang, X., Xu, P., Ji, X., Chi, T., Liu, P. et al. (2020) Tolfenamic acid inhibits GSK-3beta and PP2A mediated tau hyperphosphorylation in Alzheimer’s disease models. J. Physiol Sci. 70, 29, https://doi.org/10.1186/s12576-020-00757-y

151 Liu, P., Li, Y., Yang, W., Liu, D., Ji, X., Chi, T. et al. (2019) Prevention of Huntington’s disease-like behavioral deficits in R6/1 mouse by tolfenamic acid is associated with decreases in mutant huntingtin and oxidative stress. Oxid. Med. Cell. Longev. 2019, 4032428, https://doi.org/10.1155/2019/4032428

152 Aleo, S.J., Del Dotto, V., Fogazza, M., Maresca, A., Lodi, T., Goffrini, P. et al. (2021) Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations. Hum. Mol. Genet. 29, 3631–3645, https://doi.org/10.1093/hmg/ddaa244

153 Adwan, L., Subalea, G.M., Basha, R. and Zawia, N.H. (2015) Tolfenamic acid reduces tau and CDK5 levels: Implications for dementia and tauopathies. J. Neurochem. 133, 266–272, https://doi.org/10.1111/jnc.12960